Quote:
Originally Posted by PorscheGAL
Thank you for the response. This is exactly the kind of info I need to research the opportunity. My understanding is: that although Afrezza was FDA approved several years ago, they are just now in the position to create a sales and education team. That may be why it has never come up with your care team?
|
I just read a piece on diabetes strong about Afrezza vs Humalog, which is what I use. I guess I would approach this with caution from a potential employment standpoint. If the delivery mechanism is still the same as in set units of 4,8, 12, I can't see using it. I am active and try and maintain a tight control. I am regularly dosing 1-4 units. The lowest dose of Afrezza is the equivalent of 1.5 of Humalog and it acts much quicker. I read it can also cause a cough in over 20% of users.
If I were to use it, it would likely be rarely, and a 3rd product I have to keep track of. No thanks. Given how long it has been approved by the FDA and the limited number of users vs. MDI or pump, I am making an educated guess that the potential market is very limited.